Clinical-stage biotech firm BioAegis Therapeutics has entered a strategic collaboration with Prenosis to accelerate the development of a precision medicine approach for inflammatory diseases, with an initial focus on Acute Respiratory Distress Syndrome. The partnership aims to identify biomarkers and patient subgroups most likely to benefit from BioAegis’ investigational gelsolin-based therapy.
At the center of BioAegis’ pipeline is plasma gelsolin, a naturally occurring protein that plays a key role in regulating inflammation and supporting immune function. Unlike traditional anti-inflammatory drugs that suppress immune responses, gelsolin is designed to rebalance inflammation while preserving the body’s ability to fight infections. This distinction could prove critical in severe conditions such as ARDS, where immune dysfunction and excessive inflammation can lead to life-threatening respiratory failure.
Under the agreement, Prenosis will deploy its artificial intelligence-driven precision medicine platform to analyze clinical and biological data from BioAegis’ ongoing Phase 2 trial, known as BTI-203. The global study is enrolling approximately 600 patients across the United States, Canada, and Europe, evaluating recombinant human plasma gelsolin (rhu-pGSN) in patients with moderate-to-severe ARDS. By integrating biospecimens with clinical data, Prenosis aims to uncover biological signatures that predict which patients are most likely to respond to the therapy.
Executives from both companies emphasized the potential of combining therapeutic innovation with advanced analytics. Susan Levinson, chief executive officer of BioAegis, said the collaboration reflects a broader shift toward integrating host-directed therapies with data-driven insights. She expressed confidence that the partnership could help reshape how inflammatory diseases are treated.
Similarly, Bobby Reddy Jr., co-founder and CEO of Prenosis, noted that the collaboration aligns with the company’s vision of tailoring treatment decisions to each patient’s unique biological profile. Prenosis’ platform leverages machine learning to identify meaningful patterns in complex diseases, with a growing emphasis on critical care applications such as sepsis and ARDS.
The collaboration also builds on Prenosis’ recent momentum, including a $20 million contract from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services. The funding supports the development of AI-enabled diagnostics designed to match patients with the most effective therapies—an objective closely aligned with the BioAegis partnership.
Gelsolin itself represents a promising new class of therapy. In patients experiencing severe inflammation, levels of this protein are significantly depleted. Replenishing gelsolin has been shown in preclinical and clinical studies to restore immune balance, enhance the clearance of pathogens, and reduce tissue damage. Its mechanisms include modulating inflammatory pathways such as the NLRP3 inflammasome, improving microbial clearance by immune cells, and neutralizing harmful molecules released during tissue injury.
Unlike conventional treatments that broadly suppress inflammation, recombinant gelsolin aims to correct the underlying imbalance in the immune system. This approach could offer a safer and more effective alternative for critically ill patients, particularly those with ARDS, where maintaining immune competence is essential.
As the BTI-203 trial progresses, the collaboration between BioAegis and Prenosis is expected to generate deeper insights into patient stratification and treatment response. If successful, the effort could mark a significant step forward in bringing precision medicine to the forefront of critical care, potentially improving outcomes for patients facing severe inflammatory diseases.